Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | FASN | P49327 | 17/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14162136 | 0.87 | CYP3A4 (0.46) | CYP3A4CYP2C9SLC9A1CYP2C19KCNH2 | |
| SCHEMBL4203529 | 0.86 | FASN (0.56) | FASN | |
| SCHEMBL4208379 | 0.85 | FASN (0.53) | CYP3A4CYP2C9SLC9A1CYP2C19KCNH2 | |
| SCHEMBL4173074 | 0.84 | FASN (0.57) | FASN | |
| SCHEMBL4733627 | 0.84 | FASN (0.61) | FASN | |
| SCHEMBL4168210 | 0.84 | FASN (0.64) | FASN | |
| SCHEMBL30010047 | 0.84 | FASN (0.64) | FASN | |
| SCHEMBL4735661 | 0.83 | SLC9A1 (0.57) | SLC9A1FASN | |
| SCHEMBL4177247 | 0.83 | FASN (0.59) | FASN | |
| SCHEMBL4187300 | 0.81 | FASN (0.56) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2008075064-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF OBESITY | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008059214-A1 | BISAMLDE DERIVATIVES AND USE THEREOF AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | GPR119, FABP4, FASN | CYP3A4 3112/4885CYP2C9 3106/4885SLC9A1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.